These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


472 related items for PubMed ID: 17418548

  • 1. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
    Lohrmann M, Kappl M, Butt HJ, Urbanetz NA, Lippold BC.
    Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
    [Abstract] [Full Text] [Related]

  • 2. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW.
    Int J Pharm; 2006 Mar 09; 310(1-2):81-9. PubMed ID: 16442246
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
    Adi H, Larson I, Stewart PJ.
    Int J Pharm; 2007 Jun 07; 337(1-2):229-38. PubMed ID: 17303354
    [Abstract] [Full Text] [Related]

  • 5. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C, MacRitchie HB, Zeng XM, Martin GP.
    Int J Pharm; 2006 Dec 01; 326(1-2):39-49. PubMed ID: 16942848
    [Abstract] [Full Text] [Related]

  • 6. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances.
    Jones MD, Harris H, Hooton JC, Shur J, King GS, Mathoulin CA, Nichol K, Smith TL, Dawson ML, Ferrie AR, Price R.
    Eur J Pharm Biopharm; 2008 Jun 01; 69(2):496-507. PubMed ID: 18191553
    [Abstract] [Full Text] [Related]

  • 7. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
    Kaialy W, Martin GP, Ticehurst MD, Momin MN, Nokhodchi A.
    Int J Pharm; 2010 Jun 15; 392(1-2):178-88. PubMed ID: 20363301
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W, Martin GP, Larhrib H, Ticehurst MD, Kolosionek E, Nokhodchi A.
    Colloids Surf B Biointerfaces; 2012 Jan 01; 89():29-39. PubMed ID: 21962946
    [Abstract] [Full Text] [Related]

  • 10. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W, Ticehurst M, Nokhodchi A.
    Int J Pharm; 2012 Feb 28; 423(2):184-94. PubMed ID: 22197772
    [Abstract] [Full Text] [Related]

  • 11. Influence of carrier surface fines on dry powder inhalation formulations.
    Boshhiha AM, Urbanetz NA.
    Drug Dev Ind Pharm; 2009 Aug 28; 35(8):904-16. PubMed ID: 19466888
    [Abstract] [Full Text] [Related]

  • 12. Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders.
    Raula J, Lähde A, Kauppinen EI.
    Int J Pharm; 2009 Jan 05; 365(1-2):18-25. PubMed ID: 18789380
    [Abstract] [Full Text] [Related]

  • 13. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W, Ticehurst MD, Murphy J, Nokhodchi A.
    J Pharm Sci; 2011 Jul 05; 100(7):2665-84. PubMed ID: 21268026
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
    Jones MD, Buckton G.
    Int J Pharm; 2016 Jul 25; 509(1-2):419-430. PubMed ID: 27265314
    [Abstract] [Full Text] [Related]

  • 15. Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
    de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW.
    Int J Pharm; 2006 Mar 09; 310(1-2):72-80. PubMed ID: 16442248
    [Abstract] [Full Text] [Related]

  • 16. Dry powder inhaler formulation.
    Telko MJ, Hickey AJ.
    Respir Care; 2005 Sep 09; 50(9):1209-27. PubMed ID: 16122404
    [Abstract] [Full Text] [Related]

  • 17. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2010 Nov 09; 76(3):464-9. PubMed ID: 20854906
    [Abstract] [Full Text] [Related]

  • 18. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
    Thi TH, Danède F, Descamps M, Flament MP.
    Eur J Pharm Biopharm; 2008 Sep 09; 70(1):380-8. PubMed ID: 18504120
    [Abstract] [Full Text] [Related]

  • 19. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H, Markefka P, teWierik H, Kammelar R.
    Int J Pharm; 2006 Feb 17; 309(1-2):51-9. PubMed ID: 16377105
    [Abstract] [Full Text] [Related]

  • 20. Influence of carrier on the performance of dry powder inhalers.
    Saint-Lorant G, Leterme P, Gayot A, Flament MP.
    Int J Pharm; 2007 Apr 04; 334(1-2):85-91. PubMed ID: 17113733
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 24.